Remote HCP engagement – still a struggle for life science companies
Regulator cites issues with manufacturing plant
Troubled generics giant Teva is continuing the heavy pruning of its business and has cut a novel migraine drug from its pipeline.
Aimovig notches up another late-stage trial success
NICE calls for further discounts on beta-interferons and Copaxone